来源:@CGTNGlobalBusiness微博
#真财实料#【中国生物制药CEO:政策、研发和人才驱动中国医药领域发展】中国生物制药有限公司首席执行官谢承润在#2026冬季达沃斯#现场接受CGTN记者何静宜采访时表示,中国医药健康领域正持续强劲增长。他指出,政策支持、企业研发投入与人才红利是三大关键动力。 China's pharmaceutical-biotech sector is poised for sustained growth, driven by policy support, corporate R&D, and talent dividends, said Eric Tse, CEO of Sino Biopharmaceutical Ltd, in an interview with CGTN's He Jingyi at the 2026Davos.